Zavante®

Management Team

Ted Schroeder
President, Chief Executive Officer, Director

Kevin Finney
Chief Operating Officer

Evelyn Ellis-Grosse, PhD
Chief Scientific Officer

Cam Gallagher
Chief Business Officer

Richard Vincent
Chief Financial Officer

Robert DiVasto, PE
Senior Vice President, Manufacturing and Supply

Kristina Haeckl
Vice President of Regulatory Affairs and Quality Systems

David Skarinsky
Vice President of Clinical Operations

Paul Eckburg, MD
Acting Chief Medical Officer

Kim Sweeney, PharmD
Sr. Director, Medical Affairs

Board of Directors

Cam Garner
Chairman

Ted Schroeder
President, Chief Executive Officer, and Director

Patrick Heron
Director, Frazier Healthcare Partners

David Hirsch, MD, PhD
Director, Longitude Capital

Stephen Newman, MD
Independent Board Member

Andrew N. Schiff, MD
Observer, Aisling Capital

About Zavante Therapeutics

Zavante is passionately committed to improving the care and outcomes of hospitalized patients by identifying, developing and commercializing novel therapeutics that address significant unmet medical needs

Zavante's lead product candidate is an investigational, first-in-class injectable antibiotic under development to combat serious, life threatening infections, including those due to multi-drug resistant (MDR) bacteria.

The company is backed by leading life science investors Frazier Healthcare Partners, Longitude Capital and Aisling Capital. In 2017, Zavante completed its pivotal trial for antibiotic drug candidate, ZOLYD™ (fosfomycin for injection). If ZOLYD demonstrates efficacy and safety for the treatment of complicated urinary tract infections (cUTI), the product's first indication, Zavante expects to file a New Drug Application utilizing the FDA's 505(b)(2) pathway in early 2018.

Zavante® Timeline & Financing History

September 2014	ZOLYD™ granted QIDP designation for cUTI
June 2015	Zavante Therapeutics secures first private investment
December 2015	FDA agrees single pivotal trial for ZOLYD
December 2015	Four additional indications granted QIDP designation
December 2015	Fast-track granted for all five indications
December 2015	Zavante raised $10+ million convertible notes
March 2016	Zavante raised $35 million new Series A financing
July 2016	First patient enrolled in ZOLYD ZEUS™ study
August 2016	Infectious disease experts join Scientific Advisory Board
January 2017	ZOLYD ZEUS study enrollment, treatment completed

Therapeutic Focus

Growing antimicrobial resistance creates a significant demand for novel therapies.

Zavante believes it is uniquely poised to address the critical need for new and effective antibiotics through the development of ZOLYD™ (fosfomycin for injection), a first-in-class injectable antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against MDR pathogens associated with life-threatening infections, such as carbapenem resistant enterobacteriaceae.

Bacterial resistance to currently available antimicrobials has reached alarmingly high levels in recent decades, resulting in a global health crisis. To combat this threat, antibiotic treatment options with differing mechanisms of action are critically needed, particularly agents with activity against MDR Gram-negative bacteria.

Zavante®

"The lack of available and effective antibiotics for these life-threatening multidrug-resistant pathogens has created an important unmet medical need. An antibiotic with a unique mechanism of action like ZOLYD would be an important addition to our antibacterial armamentarium when treating seriously ill patients in the hospital."

George Drusano, MD,
Professor of Medicine and Director of the Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida

Upcoming Milestones

- ZEUS™ study topline data expected in April 2017.
- New Drug Application for ZOLYD™ expected to be filed with FDA in early 2018.

Media Relations Contact

Ian Stone
Canale Communications
ian@canalecomm.com
619-849-5388

ZOLYD™: Addressing Hospital Infections

ZOLYD (fosfomycin for injection), is an investigational, first-in-class epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary multi-drug resistant (MDR) strains that threaten hospitalized patients. The company believes that these attributes, along with extensive clinical experience outside of the U.S., support ZOLYD as a first-line treatment for complicated urinary tract infections (cUTI) suspected to be caused by MDR pathogens. Non-clinical data have shown that ZOLYD acts synergistically with certain other antibiotics to improve bacterial killing and restore susceptibility to infective agents otherwise demonstrating resistance.

The pivotal ZEUS™ (**Z**TI-01 **E**fficacy and **S**afety) study was designed to obtain regulatory approval for the treatment of cUTI, including acute pyelonephritis. Approximately 25% of cUTIs are caused by multi-drug resistant bacteria with limited treatment options available. Fosfomycin IV has an established safety profile based upon its use in markets outside the U.S., where it has been utilized for over 40 years in nine indications. ZOLYD utilizes a new dosing approach to optimize the compound's pharmacokinetics and pharmacodynamics.

The FDA has granted ZOLYD Qualified Infectious Disease Product (QIDP) and Fast Track designations for:

- Complicated urinary tract infections (cUTI)
- Complicated intra-abdominal infections (cIAI)
- Hospital-acquired bacterial pneumonia (HABP)/ Ventilator-associated bacterial pneumonia (VABP)
- Acute bacterial skin and skin structure infections (ABSSSI)

These designations make ZOLYD eligible for certain incentives available for the development of new antibiotics, including priority FDA review and an additional five years of market exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act.



ZOLYD is an investigational medication that has not been found by the U.S. Food and Drug Administration to be safe or effective for any indication. This fact sheet contains forward-looking statements within the meaning of U.S. federal securities laws, including statements about the anticipated effectiveness of ZOLYD in treating serious infections in hospitalized patients, and the company's plans and timing for submitting a new drug application for ZOLYD. The company's actual results may differ materially from those indicated in the forward-looking statements. March 2017